PRSS35 and neoplasm: Since the tumor-suppressive activity of PRSS35 appeared to depend on the in vivo microenvironment, we focused our study on CXCL2 as a candidate substrate, given its well-established role as a chemokine in the tumor immune microenvironment42–44.